Scancell (LON:SCLP) Trading Down 17.6% – Here’s What Happened
by Mitch Edgeman · The Markets DailyShares of Scancell Holdings plc (LON:SCLP – Get Free Report) traded down 17.6% on Thursday . The company traded as low as GBX 9.90 and last traded at GBX 10.50. Approximately 17,677,387 shares were traded during mid-day trading, an increase of 771% from the average daily volume of 2,029,101 shares. The stock had previously closed at GBX 12.75.
Scancell Trading Down 17.6%
The company has a market cap of £108.97 million, a PE ratio of -19.09 and a beta of 0.74. The stock’s 50 day moving average is GBX 19.16 and its 200-day moving average is GBX 15.13. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.